Chong Kun Dang gets rights to Can-Fite's liver cancer candidate in South Korea; deal expanded to include NASH
Executive Summary
Can-Fite BioPharma Ltd. granted Chong Kun Dang Pharmaceutical Corp. (CKD) exclusive rights to sell its liver cancer candidate CF102 in South Korea.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice